Salsalate Efficacy on Treatment of Fatty Liver in Diabetes; Clinical Trial in Diabetic and Prediabetic Patients

Document Type : Original Article(s)

Authors

1 Endocrinologist, Endocrinology and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Endocrinology and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Associate Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Nearly two-third of patients with type II diabetes have degrees of fatty liver; this may induce some side effects in them. This study aimed to find effect of salsalate on treatment of steatohepatitis and correlation of fatty liver with metabolic syndrome in the setting of impaired glucose metabolism.Methods: In a double-blind randomized trial within two distinct groups i.e. recently diagnosed diabetics and prediabetic cases allocated in two arms of the intervention to receive 3 g salsalate or placebo. All cases underwent glucose and lipid level studies and liver ultrasound study.Finding: Within 46 patients with diabetes, 34 (74%) had fatty liver in ultrasound; this ratio was 75 percent in 113 prediabetic cases. Relative frequency of fatty liver stages did not differ between diabetics and prediabetics. Within diabetics, mean AST level of fatty liver cases (23 ± 7 IU/dl) was higher than others (18 ± 3 IU/dl) (P < 0.05). Changes in transaminase levels following intervention did not significantly differ, comparing drug and placebo arms in two subgroups.Conclusion: According to the findings, if diabetes could be assumed as the logical consequence of prediabetic state, it seems that fatty liver did develop before this preliminary status. In this study, salsalate could not change biochemical markers of fatty liver significantly.

Keywords

References

  1. Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009; 41(4): 265-78.
  2. Chen J, Mathew M, Finch J, Cusi K. The prevalence of NAFLD in T2DM is highest among Hispanics and is closely related to hepatic and adipose tissue insulin resistance [abstract]. Diabetes 2009; 58(Suppl 1).
  3. Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep 2007; 7(3): 175-80.
  4. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51(11): 1947-53.
  5. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44(4): 865-73.
  6. Tataranni PA, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 2005; 54(4): 917-27.
  7. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444(7121): 860-7.
  8. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116(7): 1793-801.
  9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32(Supplement 1): S62-7.
  10. Mihmanli I, Kantarci F, Yilmaz MH, Gurses B, Selcuk D, Ogut G, et al. Effect of diffuse fatty infiltration of the liver on hepatic artery re-sistance index. J Clin Ultrasound 2005; 33(3): 95-9.
  11. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46(4): 1081-90.
  12. Fracanzani AL, Valenti L, Bugianesi E, Andreo-letti M, Colli A, Vanni E , et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48(3): 792-8.
  13. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008; 1(1): 36-43.
  14. Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009; 52(3): 385-93.
  15. Fleischman A, Shoelson SE, Bernier R, Gold-fine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008; 31(2): 289-94.
Journal of Isfahan Medical School
Volume 28, Issue 116 - Serial Number 116
September and October 2011
Pages 1024-1031

Files

History

  • Receive Date: 29 January 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics